- Home
- OCGN vs GNFT Comparison
OCGN vs GNFT Comparison
Compare OCGN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- GNFT
- Stock Information
- Founded
- OCGN 2013
- GNFT 1999
- Country
- OCGN United States
- GNFT France
- Employees
- OCGN N/A
- GNFT N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCGN Health Care
- GNFT Health Care
- Exchange
- OCGN Nasdaq
- GNFT Nasdaq
- Market Cap
- OCGN 205.2M
- GNFT 214.5M
- IPO Year
- OCGN N/A
- GNFT 2019
- Fundamental
- Price
- OCGN $0.84
- GNFT $4.28
- Analyst Decision
- OCGN Strong Buy
- GNFT Strong Buy
- Analyst Count
- OCGN 3
- GNFT 1
- Target Price
- OCGN $6.00
- GNFT $13.00
- AVG Volume (30 Days)
- OCGN 4.8M
- GNFT 9.9K
- Earning Date
- OCGN 05-09-2025
- GNFT 04-24-2025
- Dividend Yield
- OCGN N/A
- GNFT N/A
- EPS Growth
- OCGN N/A
- GNFT N/A
- EPS
- OCGN N/A
- GNFT 0.03
- Revenue
- OCGN $4,522,000.00
- GNFT $73,187,701.00
- Revenue This Year
- OCGN N/A
- GNFT $15.98
- Revenue Next Year
- OCGN N/A
- GNFT N/A
- P/E Ratio
- OCGN N/A
- GNFT $145.64
- Revenue Growth
- OCGN N/A
- GNFT 105.01
- 52 Week Low
- OCGN $0.52
- GNFT $2.55
- 52 Week High
- OCGN $1.98
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- OCGN 56.85
- GNFT 54.04
- Support Level
- OCGN $0.64
- GNFT $4.22
- Resistance Level
- OCGN $0.81
- GNFT $4.39
- Average True Range (ATR)
- OCGN 0.09
- GNFT 0.22
- MACD
- OCGN 0.00
- GNFT -0.01
- Stochastic Oscillator
- OCGN 53.30
- GNFT 63.93
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.